You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors

  • Authors: Bruce Kirkham, BA, MD, FRCP, FRACP; Alexis Ogdie, MD, MSCE; Fabian Proft, MD
  • CME / ABIM MOC Released: 3/9/2023
  • Valid for credit through: 3/9/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of rheumatologists, dermatologists, and primary care physicians.

The goal of this activity is for learners to be better able to discuss key clinical data on emerging therapies for spondyloarthritis and the potential for these novel agents to improve outcomes for patients in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for the use of novel therapies in spondyloarthritis
    • Clinical data for novel therapies in spondyloarthritis
  • Demonstrate greater confidence in their ability to
    • Manage patients with spondyloarthritis to optimize patient outcomes


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Bruce Kirkham, BA, MD, FRCP, FRACP

    Professor of Translational Rheumatology
    King's College London
    Consultant Rheumatologist
    Guy's and St Thomas' NHS Foundation Trust
    London, United Kingdom

    Disclosures

    Bruce Kirkham, BA, MD, FRCP, FRACP, has the following relevant financial relationships:
    Consultant or advisor for: Eli Lilly and Company; Galapagos; Novartis; Pfizer; UCB
    Speaker or member of speakers bureau for: AbbVie, Inc.; Eli Lilly and Company; Galapagos; Janssen; Novartis; Pfizer, Inc.; UCB

  • Alexis Ogdie, MD, MSCE

    Associate Professor of Medicine
    Director
    Penn Psoriatic Arthritis Clinic and Penn Center for Clinical Epidemiology and Biostatistics
    Perelman School of Medicine
    Philadelphia, Pennsylvania, United States

    Disclosures

    Alexis Ogdie, MD, MSCE, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Corrona; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
    Research funding from: AbbVie, Inc.; Amgen, Inc.; Novartis; Pfizer, Inc.

  • Fabian Proft, MD

    Department of Gastroenterology, Infectiology, and Rheumatology
    Charité University Hospital
    Berlin, Germany

    Disclosures

    Fabian Proft, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Hexal; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Roche; UCB Pharma, Inc.
    Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Hexal; Merck Sharp & Dohme; Novartis; Pfizer, Inc.; Roche; UCB Pharma, Inc.
    Research funding from: Eli Lilly and Company; Novartis; UCB Pharma, Inc.

Editors

  • Marinella Calle, PhD, CMPP

    Senior Medical Education Director, WebMD Global, LLC

    Disclosures

    Marinella Calle, PhD, CMPP, has no relevant financial relationships.

  • Diana Lucifero, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors

processing....

  • Print